ADA 2026: New GLP-1 Oral Drug, Semaglutide-Amylin Combo, and Chinese Mazdutide Data Highlighted
By
Jennifer Abbasi1
Summary
An interview with Dr. Rita Kalyani, the ADA's chief scientific and medical officer, discussing key research presented at the ADA 2026 Scientific Sessions in New Orleans. Topics include an investigational oral GLP-1 receptor agonist for diabetes, a combination injection of semaglutide with an amylin analogue, and data from China on high-dose mazdutide, among other diabetes-related research findings.
Source
Twitter / XADA 2026: New GLP-1 Oral Drug, Semaglutide-Amylin Combo, and Chinese Mazdutide Data Highlightedja.maKey quotes
· 2 pulledAn investigational oral glucagon-like peptide-1 (GLP-1) receptor agonist for diabetes, an injection that combines semaglutide with an amylin analogue, data from China on high-dose mazdutide, and more were on the docket at the American Diabetes Association (ADA) annual flagship meeting.
Rita Kalyani, MD, MHS, the ADA's chief scientific and medical officer and a professor of medicine at Johns Hopkins University School of Medicine, sat down with JAMA Medical News to share some of the important new research.
You might also wanna read
Semaglutide Shows Chondroprotective Effects in Osteoarthritis Through Weight Loss-Independent Metabolic Mechanism
This research article demonstrates that semaglutide, a GLP-1 receptor agonist, provides chondroprotective effects in osteoarthritis mouse mo
AI Analysis of Reddit Posts Identifies Potential Side Effects of GLP-1 Weight Loss Drugs
Researchers at the University of Pennsylvania used AI to analyze over 410,000 Reddit posts spanning six years to identify potential side eff
sciencealert.com·18d ago
GLP-1 Medications Show Promise for Treating Addiction Through Brain Reward Pathways
The article explores the emerging potential of GLP-1 medications like Ozempic to treat various addictions beyond their original diabetes and
newyorker.com·4mo ago
GLP-1 Drugs Linked to 30% Lower Breast Cancer Risk in New Study
New research published in the Journal of Clinical Oncology suggests GLP-1 weight loss medications may reduce cancer risk. An observational s
forbes.com·10d ago
Triple hormone drug retatrutide shows promise for diabetes and weight loss in Lancet trial
A new triple hormone drug called retatrutide, which mimics GLP-1, GIP, and glucagon, has shown promising results in a Lancet-published trial
theguardian.com·16d ago
GLP-1 Receptor Agonists Show Promise for Treating Extragenital Lichen Sclerosus: A Case Report
This case report describes two patients with extragenital lichen sclerosus, a chronic inflammatory skin condition, whose symptoms improved s
doi.org·27d agoComments
Sign in to join the conversation.
No comments yet. Be the first.